The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD.

Full Abstract

Pharmacotherapy plays a primary role in the management of attention-deficit/hyperactivity disorder (ADHD), despite the availability of effective behavioral interventions. Psychostimulants are the most commonly prescribed form of pharmacotherapy for patients with ADHD and their benefits in managed care are severalfold, leading not only to symptom resolution and improved quality of life for patients, but also reduced costs for payers and purchasers. The use of these agents requires careful consideration and management by health plan stakeholders for optimal effectiveness. Concerns regarding medication adherence, in addition to the potential for diversion and abuse of psychostimulants, highlight the importance of effective pharmacotherapy management in patients with ADHD. Initiatives promoting medication adherence, such as patient/parent education, provider follow-up, and adverse effect management, are crucial for ensuring treatment success. Once-daily, extended-release formulations of stimulants may also contribute to improving medication adherence, as may managed care pharmacy interventions such as pharmacy database monitoring.

Author information

Author/s: Dopheide, Julie A (JA);

Affiliation: Psychiatry and the Behavioral Sciences, University of Southern California, Schools of Pharmacy and Medicine, 1985 Zonal Ave, Los Angeles, CA 90089, USA. dopheide(-atsign-)pharmacy.usc.edu

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: The American journal of managed care (Am J Manag Care), published in United States. (Language: eng)

Reference: 2009-May; vol 15 (issue 5 Suppl) : pp S141-50

Dates: Created 2009/07/15; Completed 2009/10/08;

PMID: 19601689, status: MEDLINE (last retrieval date: 10/8/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: Adrenergic Uptake Inhibitors (0) ; Central Nervous System Stimulants (0) ; Propylamines (0) ; Methylphenidate (113-45-1) ; Dextroamphetamine (51-64-9) ; atomoxetine (83015-26-3)

These are the highest related articles currently in the database: